Researcher:
Osmanbaşoğlu, Emre

Profile Picture
ORCID

Job Title

Doctor

First Name

Emre

Last Name

Osmanbaşoğlu

Name

Name Variants

Osmanbaşoğlu, Emre

Email Address

Birth Date

Filters

2020 - 20213

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.bdd5707b-c982-42b5-9308-f33b2126e344

Search Results

Now showing 1 - 3 of 3
  • Placeholder
    PublicationMetadata only
    Intravascular large B-cell lymphoma within the appendix presenting as acute abdomen: a challenging diagnosis for hematologists
    (Galenos Yayıncılık, 2021) N/A; N/A; N/A; N/A; N/A; N/A; Atalar, Semra Cemre; Akay, Olga Meltem; Osmanbaşoğlu, Emre; Masyan, Helin; Taşkın, Orhun Çığ; Ferhanoğlu, Ahmet Burhan; Undergraduate Student; Faculty Member; Doctor; Doctor; Faculty Member; Faculty Member; School of Medicine; School of Medicine; N/A; N/A; School of Medicine; School of Medicine; Koç University Hospital; 346260; 170966; N/A; N/A; 166686; 18320
    N/A
  • Thumbnail Image
    PublicationOpen Access
    Hiv-associated non hodgkin lymphoma: a case series study from Turkey
    (African Traditional Herbal Medicine Supporters Initiative, 2020) Somay, Kayra; Çöpür, Sidar; Osmanbaşoğlu, Emre; Masyan, Helin; Arslan, Harun; Akay, Olga Meltem; Tekin, Süda; Ferhanoğlu, Ahmet Burhan; Researcher; Faculty Member; Faculty Member; School of Medicine; Koç University Hospital; N/A; N/A; N/A; N/A; N/A; N/A; N/A; 18320
    Background: human immunodeficiency virus (HIV) is a global health concern with major risks for opportunistic infections and predisposition to malignancies including Kaposi sarcoma associated with Human Herpes Virus-8 (HHV-8) and non-Hodgkin lymphoma (NHL) commonly associated with Epstein Barr Virus (EBV). Although the exact mechanisms of predisposition to certain malignancies are unclear, HIV (+) cancer patients typically have poorer prognosis. Materials and methods: we included all five HIV positive NHL patients receiving antiretroviral therapy (ART) and chemotherapy in our clinic and aim to determine their follow-up outcomes associated with ART. Results: the use of ART in conjunction with chemotherapy regimens lead to better therapeutic outcome in our cases with no mortality over three years of follow-up despite high rates of poor prognostic factors and studies demonstrating 1-year survival rates of approximately 30% in HIV-associated lymphoma. No significant adverse effect has been recorded. Conclusion: we recommend use of ART along with chemotherapy regimens in HIV positive lymphoma patients for better treatment response.
  • Thumbnail Image
    PublicationOpen Access
    Larynx angioedema as a signal in chronic lymphocytic leukemia: a case based guide for acquired angioedema in the setting of lymphoproliferative disorders
    (Buluş Design, 2021) Öztürk, Erman; Öztürk, Ayşe Bilge; Kısakürek, Zeynep Büşra; Sönmez, Sadi Can; Osmanbaşoğlu, Emre; Faculty Member; School of Medicine; Koç University Hospital; 147629; N/A; N/A; N/A
    Patients with angioedema can present to the internal medicine, emergency medicine, dermatology, or ear nose throat clinics. Physicians may need to assess the patients whose angioedema is unresponsive to antihistamines systematically in collaboration with other subspecialties including hematology, rheumatology, allergy, and immunology. We aimed to provide a concise review of the diagnosis and multi-disciplinary management of acquired angioedema through a case presentation. A 61-year-old woman presented with recurrent angioedema of 4 episodes within one year. She was evaluated by various disciplines such as dermatology and emergency medicine. Antihistamines and steroids were not effective. The complete blood count (CBC) results indicated lymphocytosis (lymphocyte count=9100 k/mu L) and further evaluation of the lymphocytosis with flow cytometry immunophenotyping confirmed a diagnosis of chronic lymphocytic leukemia. Since the acquired angioedema diagnosis was confirmed with low C4, C1q, and C1 esterase inhibitor levels, Rituximab 375 mg/m(2) was administered once a week for 4 weeks. The frequency of attacks decreased after rituximab therapy and none of them were life-threatening. In conclusion, when the effective treatment is initiated for the primary diagnosis in acquired angioedema, the numerous emergency department visits, hospitalizations, and the mortality due to life-threatening angioedema episodes can be avoided.